Full Text
Cost-Effectiveness Analysis of Midostaurin (MIDO) With Standard of Care (SOC) for Acute Myeloid Leukemia (AML) in Canada

Abstract

Authors

G Tremblay M Dolph K El Ouagari P Brandt A Forsythe

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×